MX2023004089A - Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. - Google Patents

Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.

Info

Publication number
MX2023004089A
MX2023004089A MX2023004089A MX2023004089A MX2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A MX 2023004089 A MX2023004089 A MX 2023004089A
Authority
MX
Mexico
Prior art keywords
adc
bind
methods
proteins
drug conjugates
Prior art date
Application number
MX2023004089A
Other languages
English (en)
Inventor
Elaina Marie Gartner
Eric John Chown
Tina Kim-Hafken
Dana Ann Kennedy
Original Assignee
Agensys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agensys Inc filed Critical Agensys Inc
Publication of MX2023004089A publication Critical patent/MX2023004089A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Abstract

En el presente documento se proporcionan métodos para tratar cánceres con conjugados de anticuerpo y fármaco (ADC) que se unen a la proteína 191P4D12 (Nectina-4).
MX2023004089A 2020-10-11 2021-10-08 Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12. MX2023004089A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063090272P 2020-10-11 2020-10-11
US202163148038P 2021-02-10 2021-02-10
US202163193493P 2021-05-26 2021-05-26
PCT/US2021/054084 WO2022076767A1 (en) 2020-10-11 2021-10-08 Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins

Publications (1)

Publication Number Publication Date
MX2023004089A true MX2023004089A (es) 2023-06-28

Family

ID=81125466

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004089A MX2023004089A (es) 2020-10-11 2021-10-08 Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.

Country Status (10)

Country Link
US (1) US20230364254A1 (es)
EP (1) EP4225379A1 (es)
JP (1) JP2023545432A (es)
KR (1) KR20230106607A (es)
AU (1) AU2021356542A1 (es)
CA (1) CA3198359A1 (es)
IL (1) IL302006A (es)
MX (1) MX2023004089A (es)
TW (1) TW202228788A (es)
WO (1) WO2022076767A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117982672A (zh) * 2022-07-14 2024-05-07 百奥泰生物制药股份有限公司 抗Nectin-4抗体药物偶联物及应用
WO2024012536A1 (zh) * 2022-07-14 2024-01-18 百奥泰生物制药股份有限公司 抗Nectin-4抗体、其抗体药物偶联物及应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022501332A (ja) * 2018-09-19 2022-01-06 ジェネンテック， インコーポレイテッド 膀胱がんの治療方法および診断方法
AU2019392090A1 (en) * 2018-12-03 2021-06-17 Agensys, Inc. Pharmaceutical compositions comprising anti-191P4D12 antibody drug conjugates and methods of use thereof

Also Published As

Publication number Publication date
EP4225379A1 (en) 2023-08-16
WO2022076767A1 (en) 2022-04-14
JP2023545432A (ja) 2023-10-30
TW202228788A (zh) 2022-08-01
AU2021356542A1 (en) 2023-05-25
US20230364254A1 (en) 2023-11-16
IL302006A (en) 2023-06-01
CA3198359A1 (en) 2022-04-14
KR20230106607A (ko) 2023-07-13

Similar Documents

Publication Publication Date Title
CY1121023T1 (el) Συζευγματα αντισωματος φαρμακου (adc) τα οποια δεσμευονται σε 191p4d12 πρωτεϊνες
TW201713360A (en) Methods of treating cancer using compositions of antibodies and carrier proteins
MX2023004089A (es) Métodos para el tratamiento del cáncer con conjugados de fármaco y anticuerpos (adc) que se unen a las proteínas 191p4d12.
DOP2012000052A (es) Proteínas terapéuticas de unión a dll4
CO6612264A2 (es) Proteinas terapeuticas de la union a dll 4
EA201791706A1 (ru) Связывающие icos белки
EA201391449A1 (ru) Антитела против пептидов цитозоля
EA201600190A1 (ru) Анти-prlr антитела и их применение
EA202091887A1 (ru) Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
MX2013011706A (es) Proteinas novedosas de enlace a antigeno.
EA202090387A1 (ru) Белки, связывающие nkg2d, cd16 и flt3
EA202193309A1 (ru) Конъюгаты антитело к тканевому фактору-лекарственное средство и связанные способы
MX2022001731A (es) Tratamiento de cánceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteínas 191p4d12.
MX2022006289A (es) Tratamiento de canceres con conjugados anticuerpo-farmaco (adc) que se unen a las proteinas 191p4d12.
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
MX2022001947A (es) Anticuerpos que se unen a las proteinas lrp5 y metodos de uso.
BR112018008983A2 (pt) moléculas de ligação específicas para asct2 e seus usos
MX2023003059A (es) Métodos para tratar cáncer con conjugados de anticuerpo-fármaco (adc) que se unen a las proteínas 191p4d12.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
AU2021344976A9 (en) Methods for treating cancers with antibody drug conjugates (adc) that bind to 191p4d12 proteins
MX2022016232A (es) Marcadores para uso en metodos para tratar canceres con conjugados de anticuerpo y farmaco (adc).
MX2018013484A (es) Nuevos anticuerpos anti-tnfrsf21 y modos de uso.
MX2021015356A (es) Anticuerpos y fragmentos de anticuerpos anti-epcam condicionalmente activos, sus inmunoconjugados y usos de estos.
WO2023133388A3 (en) Methods for treating muscle invasive urothelial cancer or muscle invasive bladder cancer with antibody drug conjugates (adc) that bind to 191p4d12 proteins
TW202417052A (zh) 以結合191p4d12蛋白質之抗體藥物結合物(adc)組合派姆單抗(pembrolizumab)治療局部晚期或轉移性尿路上皮癌之患者之方法